Boston Scientific Corp. (BSX) Tops Q3 EPS by 5c; Issues Mixed Guidance

Boston Scientific Corp. (NYSE: BSX) reported Q3 EPS of $0.16, $0.05 better than the analyst estimate of $0.11. Revenue for the quarter came in at $1.74 billion versus the consensus estimate of $1.76 billion.

Boston Scientific Corp. sees FY2012 EPS of $0.63-0.66, which may not compare consensus of $0.42. Boston Scientific Corp. sees FY2012 revenue of $7.17-7.24 billion, versus the consensus of $7.26 billion.

Boston Scientific Corp. sees Q4 2012 EPS of $0.06-0.09, versus the consensus of $0.12. Boston Scientific Corp. sees Q4 2012 revenue of $1.74-1.82 billion, versus the consensus of $1.8 billion.

For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Corpay agrees to $100M FTC settlement over marketing practices
• Barclays says AI trade is maturing, favors greater diversification